XBiotech Inc
XBIT
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
88
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,152.20 | 53.20 | -0.58% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,543.77 | 577.63 | -1.15% |
| FTSE 100 | 10,402.44 | 69.67 | -0.67% |
| HKSE | 26,588.38 | 444.16 | -1.64% |
| NASDAQ | 22,684.03 | 382.43 | -1.66% |
| Nikkei 225 | 57,226.59 | 413.25 | -0.72% |
| NZX 50 Index | 13,265.17 | 266.31 | -1.97% |
| S&P 500 | 6,857.31 | 84.16 | -1.21% |
| S&P/ASX 200 | 8,927.00 | 45.90 | -0.51% |
| SSE Composite Index | 4,111.58 | 22.43 | -0.54% |